See more : Gamelancer Media Corp. (GMNG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunoGen, Inc. (IMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunoGen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shenzhen Coship Electronics Co., Ltd. (002052.SZ) Income Statement Analysis – Financial Results
- Americas Gold and Silver Corporation (USAS) Income Statement Analysis – Financial Results
- Fraser and Neave, Limited (FNEVY) Income Statement Analysis – Financial Results
- Myovant Sciences Ltd. (MYOV) Income Statement Analysis – Financial Results
- Arabian International Healthcare Holding Company (9530.SR) Income Statement Analysis – Financial Results
ImmunoGen, Inc. (IMGN)
About ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 108.78M | 108.78M | 132.30M | 82.27M | 53.82M | 115.45M | 48.63M | 60.00M | 85.54M | 59.90M | 35.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 38.21M | 32.09M | 35.72M | 25.96M | 7.63M | 5.88M | 4.48M | 11.18M | 3.70M | 600.00K | 400.00K | 500.00K | 500.00K | 900.00K | 1.70M | 2.70M | 3.40M | 1.00M | 800.00K |
Cost of Revenue | 176.00K | 176.00K | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.57M | 2.67M | 9.24M | 5.66M | 2.83M | 3.34M | 597.05K | -463.45K | -500.00K | -1.10M | -1.50M | -6.00M | 13.40M | 17.90M | -1.70M | -1.30M | 9.50M | 7.10M | 4.70M |
Gross Profit | 108.61M | 108.61M | 17.71M | -32.25M | -120.07M | -24.29M | -92.68M | -86.91M | -26.23M | -47.06M | -51.54M | 16.36M | 19.31M | 13.94M | 27.99M | 40.25M | 34.64M | 29.42M | 26.48M | 20.30M | 4.79M | 2.54M | 3.88M | 11.64M | 4.20M | 1.70M | 1.90M | 6.50M | -12.90M | -17.00M | 3.40M | 4.00M | -6.10M | -6.10M | -3.90M |
Gross Profit Ratio | 99.84% | 99.84% | 13.38% | -39.20% | -223.11% | -21.04% | -190.60% | -144.85% | -30.66% | -78.57% | -145.03% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 90.65% | 91.69% | 74.14% | 78.20% | 62.84% | 43.21% | 86.67% | 104.15% | 113.51% | 283.33% | 475.00% | 1,300.00% | -2,580.00% | -1,888.89% | 200.00% | 148.15% | -179.41% | -610.00% | -487.50% |
Research & Development | 213.37M | 213.37M | 114.59M | 114.52M | 173.89M | 139.74M | 141.31M | 146.92M | 111.77M | 106.96M | 87.07M | 69.19M | 63.45M | 50.28M | 45.90M | 60.01M | 45.84M | 40.91M | 30.54M | 22.22M | 23.43M | 17.69M | 15.21M | 8.88M | 6.10M | 6.60M | 7.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 43.81M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 72.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 116.13M | 116.13M | 38.60M | 38.49M | 36.72M | 33.91M | 38.53M | 36.92M | 28.23M | 24.47M | 21.47M | 20.42M | 16.04M | 14.90M | 13.90M | 14.35M | 11.03M | 9.90M | 8.77M | 6.63M | 5.96M | 5.40M | 4.48M | 3.06M | 1.80M | 1.70M | 2.20M | 1.80M | 3.00M | 4.50M | 20.20M | 18.00M | 1.40M | 1.40M | 1.00M |
Other Expenses | 3.35M | 3.35M | 1.21M | 5.01M | 3.33M | 2.61M | 0.00 | 304.00K | -848.00K | 167.00K | 198.00K | 64.68M | 56.20M | 44.92M | 38.34M | 44.98M | 23.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
Operating Expenses | 329.50M | 329.50M | 153.19M | 153.01M | 210.60M | 173.65M | 43.54M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 56.87M | 50.81M | 39.30M | 28.86M | 29.39M | 23.10M | 19.69M | 12.40M | 8.40M | 9.40M | 11.10M | 17.40M | 6.40M | 6.50M | 21.90M | 19.30M | 2.50M | 2.10M | 1.30M |
Cost & Expenses | 329.68M | 329.68M | 153.19M | 153.01M | 210.60M | 173.65M | 184.85M | 183.83M | 140.00M | 131.43M | 108.54M | 89.61M | 79.49M | 65.18M | 59.80M | 74.36M | 60.44M | 53.47M | 48.54M | 34.51M | 32.22M | 26.44M | 20.29M | 11.94M | 7.90M | 8.30M | 9.60M | 11.40M | 19.80M | 24.40M | 20.20M | 18.00M | 12.00M | 9.20M | 6.00M |
Interest Income | 4.34M | 51.00K | 729.00K | 4.42M | 0.00 | 0.00 | 20.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 4.17M | 4.17M | 23.20M | 16.97M | 10.73M | 16.72M | 0.00 | 20.13M | 5.44M | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 221.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
Depreciation & Amortization | 3.35M | -1.08M | 115.80M | 26.45M | 7.41M | 5.96M | 6.01M | 5.33M | 5.51M | 4.60M | 4.64M | 4.63M | 4.94M | 4.84M | 5.00M | 3.93M | 3.15M | 2.69M | 2.22M | 1.29M | 1.13M | 984.76K | 612.82K | 463.45K | 500.00K | 1.10M | 1.50M | 6.00M | 3.40M | 2.00M | 1.70M | 1.30M | 1.10M | 700.00K | 300.00K |
EBITDA | -217.55M | -217.55M | -19.68M | -65.73M | -153.45M | -55.60M | -125.20M | -123.53M | -55.30M | -71.53M | -73.01M | -73.20M | -62.10M | -51.29M | -31.60M | -32.30M | -22.35M | -18.99M | -10.53M | -8.59M | -25.42M | -20.57M | -15.66M | -366.61K | -3.80M | -6.60M | -7.90M | -3.00M | -15.90M | -21.50M | -16.80M | -14.00M | -7.50M | -7.50M | -4.90M |
EBITDA Ratio | -199.98% | -199.98% | -14.88% | -79.89% | -285.15% | -48.16% | -257.46% | -205.87% | -64.65% | -119.43% | -205.46% | -447.48% | -321.69% | -367.88% | -112.89% | -80.25% | -58.48% | -59.19% | -29.47% | -33.09% | -333.30% | -349.63% | -349.69% | -3.28% | -102.70% | -1,100.00% | -1,975.00% | -600.00% | -3,180.00% | -2,388.89% | -988.24% | -518.52% | -220.59% | -750.00% | -612.50% |
Operating Income | -220.89M | -220.89M | -135.49M | -92.17M | -160.48M | -58.98M | -131.21M | -123.83M | -54.46M | -71.53M | -73.01M | -73.26M | -60.19M | -51.24M | -31.82M | -34.11M | -22.23M | -21.39M | -12.82M | -8.56M | -24.59M | -20.56M | -15.81M | -761.00K | -4.20M | -7.70M | -9.20M | -10.90M | -19.30M | -23.50M | -18.50M | -15.30M | -8.60M | -8.20M | -5.20M |
Operating Income Ratio | -203.06% | -203.06% | -102.41% | -112.04% | -298.20% | -51.09% | -269.83% | -206.37% | -63.66% | -119.43% | -205.46% | -447.86% | -311.77% | -367.46% | -113.68% | -84.75% | -58.16% | -66.65% | -35.90% | -32.97% | -322.39% | -349.41% | -353.01% | -6.81% | -113.51% | -1,283.33% | -2,300.00% | -2,180.00% | -3,860.00% | -2,611.11% | -1,088.24% | -566.67% | -252.94% | -820.00% | -650.00% |
Total Other Income/Expenses | -818.00K | -14.23M | -21.99M | -11.96M | -8.36M | -37.03M | -25.52M | -19.83M | -6.28M | 167.00K | 198.00K | -62.00K | 1.91M | 58.00K | -221.00K | 2.12M | 3.27M | 3.57M | 1.90M | 2.69M | 4.65M | 6.05M | 6.34M | 523.44K | 100.00K | 100.00K | 200.00K | -5.60M | -600.00K | -200.00K | -100.00K | 0.00 | -100.00K | -100.00K | -100.00K |
Income Before Tax | -221.71M | -221.71M | -44.37M | -104.13M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -51.18M | -32.04M | -31.99M | -18.95M | -17.82M | -10.92M | -5.87M | -19.95M | -14.50M | -9.47M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.70M | -8.30M | -5.30M |
Income Before Tax Ratio | -203.81% | -203.81% | -33.54% | -126.57% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -367.04% | -114.47% | -79.49% | -49.60% | -55.53% | -30.58% | -22.62% | -261.49% | -246.51% | -211.49% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -255.88% | -830.00% | -662.50% |
Income Tax Expense | 1.22M | 1.22M | 22.31M | 17.96M | 7.39M | 37.03M | 0.00 | 19.83M | 6.28M | -167.00K | -198.00K | 62.00K | -1.91M | -265.00K | -100.00K | 27.00K | 35.00K | 17.00K | 29.00K | 45.49K | 35.13K | 127.81K | 82.60K | 237.56K | 4.10M | 7.60M | 9.00M | 16.50M | 19.90M | 23.70M | 18.60M | 15.30M | 100.00K | 8.30M | 5.30M |
Net Income | -222.93M | -222.93M | -66.68M | -122.09M | -167.87M | -96.01M | -156.73M | -143.66M | -60.74M | -71.36M | -72.81M | -73.32M | -58.27M | -50.91M | -31.94M | -32.02M | -18.99M | -17.83M | -10.95M | -5.92M | -19.98M | -14.63M | -15.29M | -237.56K | -4.10M | -7.60M | -9.00M | -16.50M | -19.90M | -23.70M | -18.60M | -15.30M | -8.80M | -8.30M | -5.30M |
Net Income Ratio | -204.93% | -204.93% | -50.40% | -148.40% | -311.94% | -83.17% | -322.31% | -239.42% | -71.01% | -119.15% | -204.90% | -448.24% | -301.86% | -365.14% | -114.11% | -79.55% | -49.69% | -55.58% | -30.66% | -22.80% | -261.95% | -248.68% | -341.36% | -2.12% | -110.81% | -1,266.67% | -2,250.00% | -3,300.00% | -3,980.00% | -2,633.33% | -1,094.12% | -566.67% | -258.82% | -830.00% | -662.50% |
EPS | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
EPS Diluted | -0.88 | -0.88 | -0.38 | -0.82 | -1.20 | -0.98 | -1.80 | -1.65 | -0.71 | -0.83 | -0.87 | -0.95 | -0.85 | -0.87 | -0.63 | -0.75 | -0.45 | -0.43 | -0.27 | -0.15 | -0.48 | -0.37 | -0.42 | -0.01 | -0.16 | -0.31 | -0.50 | -1.32 | -1.58 | -2.09 | -1.76 | -1.58 | -1.28 | -1.46 | -3.36 |
Weighted Avg Shares Out | 253.33M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 29.52M | 25.53M | 24.21M | 17.86M | 12.50M | 12.57M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
Weighted Avg Shares Out (Dil) | 253.63M | 253.63M | 176.15M | 148.31M | 139.95M | 98.07M | 87.08M | 86.98M | 86.04M | 85.48M | 84.06M | 76.81M | 68.92M | 58.85M | 51.07M | 42.97M | 41.76M | 41.18M | 40.87M | 40.65M | 41.91M | 39.62M | 36.68M | 32.85M | 25.53M | 24.21M | 17.86M | 12.50M | 12.62M | 11.34M | 10.57M | 9.68M | 6.88M | 5.68M | 1.58M |
4 Stocks That Exhibit Solid Earnings Acceleration
Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a Bet
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Examples of How Moneyness Impacts Options Trading
ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
Source: https://incomestatements.info
Category: Stock Reports